Epidemiology and etiology of neuroblastoma: An overview

Anticancer Research

Volumn 23, Issue 1 B, 2003, Pages 755-760

  Izbicki, Tadeusz ^a   Mazur, Joanna ^b   Izbicka, Elzbieta ^b  

^a INSTITUTE OF MOTHER AND CHILD   (Poland)

^b NONE

Author keywords

Epidemiology; Etiology; Neuroblastoma

Indexed keywords

ADRENERGIC SYSTEM; CANCER REGRESSION; CARCINOGENESIS; CATECHOLAMINE EXCRETION; CHILDHOOD CANCER; HUMAN; NEUROBLASTOMA; PRIORITY JOURNAL; REVIEW;

CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; NEUROBLASTOMA;

EID: 0037236354     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. Castleberry RP: Clinical and biologic features in the prognosis and treatment of neuroblastoma. Curr Opin Oncol 4: 116-123, 1992.
2. Stiller CA and Parkin DM: Geographic and ethnic variations in the incidence of childhood cancer. Br Med Bull 52: 682-703, 1996.
3. Kaatsch P and Michaelis J: Epidemiological data on childhood malignancies in the first year of life. In: Lampert F, Cordero di Montezemolo L, and Pession A (eds.), Cancer in the First Year of Life, pp. 1-7: Karger, 1990.
4. O'Neill JA, Littman P, Blitzer P, Soper K, Chatten J and Shimada H: The role of surgery in localized neuroblastoma. J Pediatr Surg 20: 708-712, 1985.
5. Hassenbusch S, Kaizer H and White JJ: Prognostic factors in neuroblastic tumors. J Pediatr Surg 11: 287-297, 1976.
6. Joshi VV, Cantor AB, Brodeur GM, Look AT, Shuster JJ, Altshuler G, Larkin EW, Holbrook CT, Silverman JF, Norris HT et al.: Correlation between morphologic and other prognostic markers of neuroblastoma. A study of histologic grade, DNA index, N-myc gene copy number, and lactic dehydrogenase in patients in the Pediatric Oncology Group. Cancer 71: 3173-3181, 1993.
7. Young JL, Jr, Ries LG, Silverberg E, Horm JW and Miller RW: Cancer incidence, survival, and mortality for children younger than age 15 years. Cancer 58 598-602, 1986.
8. Stiller CA and Parkin DM: International variations in the incidence of neuroblastoma. Int J Cancer 52: 538-543, 1992.
9. Poplack D and Blatt J: Neuroblastoma. In: Levine A (ed.) Cancer in the Young, pp. 220-225. New York: Mason Pub, 1982.
10. Bessho F: Effects of mass screening on age-specific incidence of neuroblastoma. Int J Cancer 67: 520-522, 1996.
11. Nakagawara A, Zaizen Y, Ikeda K, Suita S, Ohgami H, Nagahara N, Sera Y, Akiyama H, Kawakami K and Uchino J: Different genomic and metabolic patterns between mass screening-positive and mass screening-negative later-presenting neuroblastomas. Cancer 68: 2037-2044, 1991.
12. Grosfeld JL, Schatzlein M, Ballantine TV, Weetman RM and Baehner RL: Metastatic neuroblastoma: factors influencing survival. J Pediatr Surg 13: 59-65, 1978.
13. Castleberry RP: Biology and treatment of neuroblastoma. Pediatr Clin North Am 44: 919-937, 1997.
14. Huddart SN, Muir KR, Parkes S, Mann JR, Stevens MC and Raafat F: Neuroblastoma: a 32-year population-based study - implications for screening. Med Pediatr Oncol 21: 96-102, 1993.
15. Allan SG, Cornbleet MA, Carmichael J, Arnott SJ and Smyth JF: Adult neuroblastoma. Report of three cases and review of the literature. Cancer 57: 2419-2421, 1986.
16. Miller R: Ethnic differences in cancer occurrences: genetic and environmental influences with particular reference to neuroblastoma. In: Mulvihill J, Miller, R, Fraumeni, J (ed.) Genetics in Human Cancer. New York: Raven Press, 1977.
17. Wilson LM and Draper GJ: Neuroblastoma, its natural history and prognosis: a study of 487 cases. Br Med J 3: 301-307, 1974.
18. Castleberry RP: Neuroblastoma. Eur J Cancer 33: 1430-1437; discussion 1437-1438, 1997.
19. Young JL Jr and Miller RW: Incidence of malignant tumors in U. S. children. J Pediatr 86: 254-258, 1975.
20. Hayes P: Neuroblastoma. In: Pizzo A and E P (eds.), Principles and Practice in Pediatric Oncology, pp. 3-18: Lippincott Company, 1989.
21. Robinson L: General principles of the epidemiology of childhood cancer. In: Pizzo A and Poplack E (eds.), Principles and Practice of Pediatric Oncology, pp. 3-9: Lippincott Company, 1989.
22. Draper GJ, Kroll ME and Stiller CA: Childhood cancer. Cancer Surv 20: 493-517, 1994.
23. Chauvin F, Mathieu P, Frappaz D, Lasset C, Favrot MC, Greffe J, Esteve J, Thiesse P, Combaret V, Chauvot P, Boschetti R, David L, Brunat-Mentigny M and Philip T: Screening for neuroblastoma in France: methodological aspects and preliminary observations. Med Pediatr Oncol 28: 81-91, 1997.
24. Acharya S, Jayabose S, Kogan SJ, Tugal O, Beneck D, Leslie D and Slim M: Prenatally diagnosed neuroblastoma. Cancer 80: 304-310, 1997.
25. Kerbl R, Urban C, Starz I, Ambros IM, Strehl S, Kovar H, Gadner H and Ambros PF: Neuroblastoma with N-myc amplification detected by urine: mass screening in infants after the sixth month of life. Med Pediatr Oncol 21: 625-626, 1993.
26. Wong KY, Hanenson IB and Lampkin BC: Familial neuroblastoma. Am J Dis Child 121: 415-416, 1971.
27. Wagget J, Aherne G and Aherne W: Familial neuroblastoma: report of two sib pairs. Arch Dis Child 48: 63-66, 1973.
28. Walach N, Novikov I, Milievskaya I, Goldzand G and Modan B: Cancer among spouses: review of 195 couples. Cancer 82: 180-185, 1998.
29. Dodge H: Neuroblastoma of the adrenal medulla in siblings. Medical Journal 42: 35-38, 1945.
30. Plochl E, Kaser H and Klein H: Excretion of catecholamines in relatives of patients with familial neuroblastoma. Cancer Res 36: 10-12, 1976.
31. Gerson JM, Chatten J and Eisman S: Letter: Familial neuroblastoma: a follow-up. N Engl J Med 290: 1487, 1974.
32. Bond JV Letter: Familial neuroblastoma and ganglioneuroma. Jama 236: 561-562, 1976.
33. Knudson AG Jr and Meadows AT: Sounding board. Regression of neuroblastoma IV-S: a genetic hypothesis. N Engl J Med 302: 1254-1256, 1980.
34. Pegelow CH, Ebbin AJ, Powars D and Towner JW: Familial neuroblastoma. J Pediatr 87: 763-765, 1975.
35. Bolande RP: Neurocristopathy: its growth and development in 20 years, Pediatr Pathol Lab Med 17: 1-25, 1997.
36. Bolande RP and Towler WF: A possible relationship of neuroblastoma to Von Recklinghausen's disease. Cancer 26: 162-175, 1970.
37. Grotting JC, Kassel S and Dehner LP: Nesidioblastosis and congenital neuroblastoma: a histologic and immunocytochemical study of a new complex neurocristopathy. Arch Pathol Lab Med 103: 642-646, 1979.
38. Carachi R, Auldist AW and Chow CW: Neuroblastoma and Hirschsprung's disease. Z Kinderchir 35: 24-25, 1982.
39. Lafer DJ: Neuroblastoma and lumbar hernia: a causal relationship? J Pediatr Surg 29: 926-929, 1994.
40. Allen RW, Jr., Ogden B, Bentley FL and Jung AL: Fetal hydantoin syndrome, neuroblastoma, and hemorrhagic disease in a neonate. Jama 244: 1464-1465, 1980.
41. Schwartzbaum JA: Influence of the mother's prenatal drug consumption on risk of neuroblastoma in the child. Am J Epidemiol 135: 1358-1367, 1992.
42. Kinney H, Faix R and Brazy J: The fetal alcohol syndrome and neuroblastoma. Pediatrics 66: 130-132, 1980.
43. Spitz MR and Johnson CC: Neuroblastoma and paternal occupation. A case-control analysis. Am J Epidemiol 121: 924-929, 1985.
44. Nigro G, Schiavetti A, Booth JC, Clerico A, Dominici C, Krzysztofiak A and Castello M: Cytomegalovirus-associated stage 4S neuroblastoma relapsed stage 4. Med Pediatr Oncol 24: 200-203, 1995.
45. Cinatl J Jr, Cinatl J, Vogel JU, Kotchetkov R, Driever PH, Kabickova H, Kornhuber B, Schwabe D and Doerr HW: Persistent human cytomegalovirus infection induces drug resistance and alteration of programmed cell death in human neuroblastoma cells. Cancer Res 58: 367-372, 1998.
46. Shinohara T, Nagashima K and Major EO: Propagation of the human polyomavirus, JCV, in human neuroblastoma cell lines. Virology 228: 269-277, 1997.
47. Izbicki T: unpublished, 2002.
48. Schwab M: Is there a neuroblastoma anti-oncogene? Prog Clin Biol Res 366: 1-9, 1991.
49. Triche TJ: Neuroblastoma and other childhood neural tumors: a review. Pediatr Pathol 10: 175-193, 1990.
50. Mora J, Cheung NK, Kushner BH, LaQuaglia MP, Kramer K, Fazzari M, Heller G, Chen L and Gerald WL: Clinical categories of neuroblastoma are associated with different patterns of loss of heterozygosity on chromosome arm 1p. J Mol Diagn 2: 37-46, 2000.
51. Caron H, Peter M, van Sluis P, Speleman F, de Kraker J, Laureys G, Michon J, Brugieres L, Voute PA, Westerveld A et al.: Evidence for two tumour suppressor loci on chromosomal bands 1p35-36 involved in neuroblastoma: one probably imprinted, another associated with N-myc amplification. Hum Mol Genet 4: 535-539, 1995.
52. Christiansen H, Sahin K, Berthold F, Hero B, Terpe HJ and Lampert F: Comparison of DNA aneuploidy, chromosome 1 abnormalities, MYCN amplification and CD44 expression as prognostic factors in neuroblastoma. Eur J Cancer 4: 541-544, 1995.
53. Franke F, Forster W, Rudolph B and Lampert F: Metastatic neuroblastoma in an infant: translocation (1;11), deletion (2) and double minute chromosomes. Eur J Pediatr 143: 305-308, 1985.
54. Look AT, Hayes FA, Nitschke R, McWilliams NB and Green AA: Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med 311: 231-235, 1984.
55. Look AT, Hayes FA, Shuster JJ, Douglass EC, Castleberry RP, Bowman LC, Smith EI and Brodeur GM: Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 9: 581-591, 1991.
56. Cohn SL, Rademaker AW, Salwen HR, Franklin WA, GonzalesCrussi F, Rosen ST and Bauer KD: Analysis of DNA ploidy and proliferative activity in relation to histology and N-myc amplification in neuroblastoma. Am J Pathol 136: 1043-1052, 1990.
57. Bown N: Neuroblastoma tumour genetics: clinical and biological aspects. J Clin Pathol 54: 897-910, 2001.
58. Lee WH, Murphree AL and Benedict WF: Expression and amplification of the N-myc gene in primary retinoblastoma. Nature 309: 458-460, 1984.
59. Wong AJ, Ruppert JM, Eggleston J, Hamilton SR, Baylin SB and Vogelstein B: Gene amplification of c-myc and N-myc in small cell carcinoma of the lung. Science 233: 461-464, 1986.
60. Nakagawara A, Ikeda K, Higashi K and Sasazuki T: Inverse correlation between N-myc amplification and catecholamine metabolism in children with advanced neuroblastoma. Surgery 107: 43-49, 1990.
61. Maris JM and Matthay KK: Molecular biology of neuroblastoma. J Clin Oncol 17: 2264-2279, 1999.
62. Cohn SL, Look AT, Joshi VV, Holbrook T, Salwen H, Chagnovich D, Chesler L, Rowe ST, Valentine MB, Komuro H et al.: Lack of correlation of N-myc gene amplification with prognosis in localized neuroblastoma: a Pediatric Oncology Group study. Cancer Res 55: 721-726, 1995.
63. Combaret V, Audoynaud C, Iacono I, Favrot MC, Schell M, Bergeron C and Puisieux A: Circulating MYCN DNA as a tumorspecific marker in neuroblastoma patients. Cancer Res 62: 3646-3648, 2002.
64. Borriello A, Roberto R, Della Ragione F and Iolascon A: Proliferate and survive: cell division cycle and apoptosis in human neuroblastoma. Haematologica 87: 196-214, 2002.
65. Lasorella A, Boldrini R, Dominici C, Donfrancesco A, Yokota Y, Inserra A and Lavarone A: Id2 is critical for cellular proliferation and is the oncogenic effector of N-myc in human neuroblastoma. Cancer Res 62: 301-306, 2002.
66. Harris CC: p53 tumor suppressor gene: from the basic research laboratory to the clinic-an abridged historical perspective. Carcinogenesis 17: 1187-1198, 1996.
67. Brambilla E, Negoescu A, Gazzeri S, Lantuejoul S, Moro D, Brambilla C and Coll JL: Apoptosis-related factors p53, Bcl-2, and Bax in neuroendocrine lung tumors. Am J Pathol 149: 1941-1952, 1996.
68. Dole M, Nunez G, Merchant AK, Maybaum J, Rode CK, Bloch CA and Castle VP: Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res 54: 3253-3259, 1994.
69. Bogenmann E, Torres M and Matsushima H: Constitutive N-myc gene expression inhibits trkA mediated neuronal differentiation. Oncogene 10: 1915-1925, 1995.
70. Nakagawara A, Arima M, Azar CG, Scavarda NJ and Brodeur GM: Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. Cancer Res 52: 1364-1368, 1992.
71. Allgayer H, Babic R, Grutzner KU, Beyer BC, Tarabichi A, Schildberg FW and Heiss MM: Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns. Clin Exp Metastasis 16: 62-73, 1998.
72. Nakagawara A, Kadomatsu K, Sato S, Kohno K, Takano H, Akazawa K, Nose Y and Kuwano M: Inverse correlation between expression of multidrug resistance gene and N-myc oncogene in human neuroblastomas. Cancer Res 50: 3043-3047, 1990.
73. Norris MD, Burkhart CA, Marshall GM, Weiss WA and Haber M: Expression of N-myc and MRP genes and their relationship to N-myc gene dosage and tumor formation in a murine neuroblastoma model. Med Pediatr Oncol 35: 585-589, 2000.
74. Tanaka T: Ha-ras p21 in neuroblastoma: a new marker in prediction of patient outcome. Prog Clin Biol Res 385: 275-280, 1994.
75. Matsunaga T, Shirasawa H, Enomoto H, Yoshida H, Iwai J, Tanabe M, Kawamura K, Etoh T and Ohnuma N: Neuronal src and trk a protooncogene expression in neuroblastomas and patient prognosis. Int J Cancer 79: 226-231, 1998.
76. Griffin ME and Bolande RP: Familial neuroblastoma with regression and maturation to ganglioneurofibroma. Pediatrics 43: 377-382, 1969.
77. Mancini AF, Rosito P, Vitelli A, Paolucci P, Vecchi V, Paolucci G, de Bernardi B, Calculli G, Carli M, Castello M et al.: IV-S neuroblastoma: a cooperative study of 30 children. Med Pediatr Oncol 12: 155-161, 1984.
78. Evans AE, Chatten J, D'Angio GJ, Gerson JM, Robinson J and Schnaufer L: A review of 17 IV-S neuroblastoma patients at the children's hospital of Philadelphia. Cancer 45: 833-839, 1980.
79. Coldman AJ, Fryer CJ, Elwood JM and Sonley MJ: Neuroblastoma: influence of age at diagnosis, stage, tumor site, and sex on prognosis. Cancer 46: 1896-1901, 1980.
80. Skowronska M: Observations regarding prognostic factors in children treated for neuroblastoma. Przegl Pediatr (Pol) VI (6): 470-478, 1978.
81. Ota K: Histopathological Classification and Altas of Tumors in Infancy and Childhood, p. 220. Tokyo: Canahara Company, 1980.
82. Hata Y, Naito H, Sasaki F, Ohkawa M, Takeda T, Sasaki M and Uchino J: Fifteen years' experience of neuroblastoma: a prognostic evaluation according to the Evans and UICC staging systems. J Pediatr Surg 25: 326-329, 1990.
83. Tsuchida Y, Hemmi H, Inoue A, Obana K, Yang HW, Hayashi Y, Kanda N and Shimatake H: Genetic clinical markers of human neuroblastoma with special reference to N-myc oncogene: amplified or not amplified? - An overview. Tumour Biol 17: 65-74, 1996.
84. Brodeur GM, Seeger RC, Barrett A, Berthold F, Castleberry RP, D'Angio G, De Bernardi B, Evans AE, Favrot M, Freeman AI et al.: International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol 6: 1874-1881, 1988.
85. Kretschmar CS, Frantz CN, Rosen EM, Cassady JR, Levey R and Sallan SE: Improved prognosis for infants with stage IV neuroblastoma, J Clin Oncol 2: 799-803, 1984.
86. Iancu TC, Shiloh H and Kedar A: Neuroblastomas contain iron-rich ferritin. Cancer 61: 2497-2502, 1988.